In February, Kenilworth-based Merck announced its women’s health, legacy brands and biosimilars spinoff business.
On Monday afternoon, the company named two c-suite leaders for the Organon & Co. business: Matthew Walsh as chief financial officer and Rachel Stahler as chief information officer.
Both Walsh and Stahler come to the new company from Madison-based Allergan.
At Organon, Walsh will lead and execute overall financial strategy, including financial planning, tax, audit, treasury, investor relations and business development. At Allergan, he served as executive vice president and chief financial officer.
Walsh has more than 15 years of public company chief financial experience, Merck said. With merger and acquisition experience including 11 additions and integrations – and five divestitures – from his nine years at Catalent, where Merck said he served as executive vice president and CFO.
As the head of the company’s technology strategy, Stahler will oversee Organon’s infrastructure, operations and delivery, working to advance digital capabilities.
At Allergan, she served as chief information officer. Prior to that she served as CIO at organizations including Syneos Health/Inventiv Health and Optimer Pharmaceuticals.
“I am pleased to welcome Matt and Rachel to the recently appointed executive leadership team for Organon,” Merck Chairman and Chief Executive Officer Kenneth Frazier said in a prepared statement. “Their deep expertise and pharmaceutical industry knowledge make them both important additions to the team at this pivotal moment in Organon’s preparation to become an independent company focused on positively impacting the lives of patients and improving public health.”
In March, Merck said it named Carrie Cox as chairman of the board for Organon, in addition to six internal appointments for the company’s executive leadership team, as it prepares for independent operation.
According to Merck, the spinoff is set to be completed in the first half of 2021.
Editor’s note: This story was updated at 11:46 a.m. EST on May 19, 2020, to reflect a correction to Rachel Stahler’s past work experience made by Merck to its press release announcing the leadership appointments.